You are in: eMedicine Specialties > Emergency Medicine > INFECTIOUS DISEASES Hand InfectionsArticle Last Updated: Feb 11, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Rohini Jonnalagadda, MD, Staff Physician, Department of Emergency Medicine, New York University/Bellevue Hospital Center Rohini Jonnalagadda is a member of the following medical societies: Sigma Xi Coauthor(s): Gregory S Johnston, MD, Assistant Professor, Department of Emergency Medicine, New York University School of Medicine; Chair, Hospital Emergency Preparedness Committee, Bellevue Hospital Center; Consulting Staff, Department of Emergency Medicine, Bellevue Hospital Center, New York University Medical Center, Tisch Hospital, Harbor Veterans Administration Medical Center Editors: Dan Danzl, MD, Chair, Department of Emergency Medicine, Professor, University of Louisville Hospital; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Eric L Weiss, MD, DTM&H, Director of Stanford Travel Medicine, Medical Director of Stanford Lifeflight, Assistant Professor, Departments of Emergency Medicine and Infectious Diseases, Stanford University School of Medicine; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Jonathan Adler, MD, Attending Physician, Department of Emergency Medicine, Massachusetts General Hospital; Division of Emergency Medicine, Harvard Medical School Author and Editor Disclosure Synonyms and related keywords: hand infection, infections of the hand, paronychia, felon, herpetic whitlow, infectious tenosynovitis, deep fascial space infections, acute paronychia, hangnails, nail biting, manicuring, finger sucking, eponychia, artificial nails, chronic paronychia, metastatic cancer, subungual melanoma, squamous cell cancer, floating nail, subungual abscess, herpes simplex virus infection of the finger, HSV infection of the finger, HSV-1, HSV-2, dorsal subaponeurotic abscess, subfascial web space infection, midpalmar space infection, thenar space infection, Staphylococcus aureus, S aureus, Streptococcus species, Candida albicans, C albicans, atypical mycobacteria, Neisseriagonorrhoeae, N gonorrhoeae, Eikenella corrodens, E corrodens, Pasteurella multocida, P multocida, Capnocytophaga species, frank abscess, osteomyelitis INTRODUCTIONBackgroundIn 1939, Kanavel, author of the landmark Infections of the Hand, observed, "In almost all cases of serious infection the difficulty is to make a correct diagnosis both as to the nature of the infection and the position of the pus." Specific infections covered in this article include paronychia, felon, herpetic whitlow, tenosynovitis, and deep fascial space infections. PathophysiologyFew structures of the body are as complex or as unique as the human hand with the functions of sensation, mobility, and strength in one small area. The hand consists of multiple compartments and planes, the knowledge of which allows one to understand the pathophysiology, diagnosis, and treatment of hand infections. Paronychia Infection of the area of the lateral nail fold (paronychium) is typically due to superficial trauma (eg, hangnails, nail biting, manicuring, finger sucking). Artificial nails have also been associated with acute paronychia. Although paronychia typically starts as a cellulitis, its progression to abscess formation is not uncommon. Infection that spreads to the proximal nail edge is termed an eponychia. Occasionally, infection can spread under the nail plate itself, resulting in a subungual abscess. Chronic paronychia resembles acute paronychia but is usually nonsuppurative. People at risk include those repeatedly exposed to water and/or irritants as well as those who are immunocompromised. Metastatic cancer, subungual melanoma, and squamous cell cancer may rarely present as chronic paronychia. Felon The distal palmar phalanx is compartmentalized by tangentially oriented fibrous septa. These septa result in a closed compartment at the distal phalanx, which helps prevent the proximal spread of infection. Infection typically is due to direct inoculation of bacteria by penetrating trauma but may be caused by hematogenous spread and by local spread from an untreated paronychia. Infection results in edema and increased pressure within the closed compartment. This, in turn, can impair venous outflow and lead to a local compartment syndrome and myonecrosis. Invasion of the bone leads to osteomyelitis. Herpetic whitlow Herpes simplex virus (HSV) infection of the distal finger typically results from direct inoculation of the virus into broken skin. Infection by type 1 or type 2 HSV is clinically indistinguishable. As in herpes infections elsewhere in the body, it is believed that the virus can remain dormant in the neural ganglia, leading to recurrent infections. Infectious tenosynovitis Tendon sheaths consist of a visceral layer adherent to the tendon and a parietal layer. Notably, the flexor tendon sheath of the thumb is continuous with the radial bursae, whereas the flexor tendon sheath of the fifth digit is continuous with the ulnar bursae. In 80% of individuals, communication exists between the radial and ulnar bursae. The tenosynovial coverings of the second, third, and fourth digits do not communicate with either the radial bursae or the ulnar bursae in most individuals. Infection can also occur by hematogenous spread, with Neisseria gonorrhoeae as the offending agent in many cases. Deep fascial space infection The deep fascial spaces of the hand are potential spaces and consist of the dorsal subaponeurotic space, subfascial web space, midpalmar space, and thenar space. The dorsal subaponeurotic space lies dorsal to the extensor tendons of the hand. The subfascial web space is contiguous with the dorsal subcutaneous space of the digits. The midpalmar space is demarcated by the palmar interosseous muscles dorsally and the flexor tendons of the third, fourth, and fifth digits ventrally. Lastly, the thenar space extends from the long metacarpal bone to the thenar eminence and consists of the area between the adductor pollicis muscle dorsally and the flexor tendon of the second digit ventrally. These compartments are susceptible to infection by direct penetrating trauma, spread from a neighboring compartment, or hematogenous seeding. Because of the dorsal location of the lymphatics, erythema and swelling commonly appear over the dorsum of the hand, even when the injury is of palmar origin. Mortality/MorbidityInfections of the hand (especially dominant-hand infections) can be devastating and frequently require admission for antibiotic therapy and/or surgical intervention. Possible complications are outlined below (see Complications). CLINICALHistory
Physical
Causes
DIFFERENTIALSBites, Animal Bites, Human Cellulitis Compartment Syndrome, Extremity Felon Fingertip Injuries Fractures, Hand Herpetic Whitlow Nailbed Injuries Osteomyelitis Paronychia Tenosynovitis
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Cephalexin (Keflex) |
|---|---|
| Description | First-generation cephalosporin that inhibits bacterial growth by inhibiting bacterial cell wall synthesis. Bactericidal and effective against rapidly growing organisms forming cell walls. Primarily active against skin flora. Typically used for skin structure coverage and as prophylaxis in minor procedures. DOC for immunocompromised patients with paronychia. |
| Adult Dose | 250-500 mg PO qid |
| Pediatric Dose | 25-50 mg/kg/d PO divided q6h |
| Contraindications | Documented hypersensitivity |
| Interactions | Aminoglycosides increase nephrotoxic potential of cephalexin |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in patients with renal impairment |
| Drug Name | Clindamycin (Cleocin) |
|---|---|
| Description | Lincosamide useful as treatment against serious skin and soft tissue infections caused by most staphylococcal strains. Also effective against aerobic and anaerobic streptococci, except enterococci. Inhibits bacterial protein synthesis by inhibiting peptide chain initiation at bacterial ribosome where it preferentially binds to 50S ribosomal subunit, causing bacterial growth inhibition. DOC for paronychia in children and those who wash dishes. |
| Adult Dose | 150-450 mg PO qid |
| Pediatric Dose | 20-30 mg/kg/d PO divided qid |
| Contraindications | Documented hypersensitivity; regional enteritis; ulcerative colitis; hepatic impairment; antibiotic-associated colitis |
| Interactions | Increases duration of neuromuscular blockade induced by tubocurarine and pancuronium; erythromycin may antagonize effects of clindamycin; antidiarrheals may delay absorption of clindamycin |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis |
| Drug Name | Ampicillin-sulbactam (Unasyn) |
|---|---|
| Description | Combination antimicrobial agent that uses a beta-lactamase inhibitor with ampicillin. Covers skin, enteric flora, and anaerobes. DOC for infectious tenosynovitis and deep fascial space infections. |
| Adult Dose | 3 g IV q6h |
| Pediatric Dose | <12 years: Not established <12 years: 25 mg/kg IV q6h (based on ampicillin component) |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid and disulfiram elevate ampicillin levels; allopurinol decreases ampicillin effects and has additive effects on ampicillin rash; may decrease effects of oral contraceptives |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Patients with renal failure may require dose adjustment; mononucleosis increases incidence of rash with ampicillin-sulbactam therapy; evaluate appearance of rash carefully to differentiate nonallergic ampicillin rash from hypersensitivity reaction |
| Drug Name | Cefazolin (Ancef, Kefzol, Zolicef) |
|---|---|
| Description | First-generation semisynthetic cephalosporin, which, by binding to 1 or more penicillin-binding proteins, arrests bacterial cell wall synthesis and inhibits bacterial growth. Primarily active against skin flora, including S aureus. Typically used alone for skin and skin-structure coverage. An alternate DOC for infectious tenosynovitis and deep fascial space infections. |
| Adult Dose | 1 g IV/IM q6h |
| Pediatric Dose | 20 mg/kg IV/IM q8h |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid prolongs effect of cefazolin; coadministration with aminoglycosides may increase renal toxicity; may yield false-positive urine-dip test for glucose |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in renal impairment; superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy |
| Drug Name | Vancomycin (Vancocin) |
|---|---|
| Description | Potent antibiotic directed against gram-positive organisms and active against Enterococcus species. Useful in treatment of septicemia and skin structure infections. Indicated for patients who cannot receive or whose conditions have not responded to penicillins and cephalosporins or for those who have infections with resistant staphylococci. For abdominal penetrating injuries, combine with agent active against enteric flora and/or anaerobes. DOC (in conjunction with gentamicin) for infectious tenosynovitis and deep fascial space infections in patients who are allergic to penicillin. To avoid toxicity, current recommendation is to assay vancomycin trough levels after third dose drawn 0.5 h prior to next dosing. Use CrCl to adjust dose in patients with renal impairment. |
| Adult Dose | 1 g IV q12h |
| Pediatric Dose | 10 mg/kg IV q6h |
| Contraindications | Documented hypersensitivity |
| Interactions | Erythema, histaminelike flushing, and anaphylactic reactions may occur when administered with anesthetic agents; taken concurrently with aminoglycosides, risk of nephrotoxicity may increase above that with aminoglycoside monotherapy; effects in neuromuscular blockade may be enhanced when coadministered with nondepolarizing muscle relaxants |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in renal failure; neutropenia; red man syndrome is caused by IV infusion that is too rapid (dose administered over a few min) but rarely happens when dose administered as 2-h administration or as PO/IP administration; red man syndrome is not an allergic reaction |
| Drug Name | Gentamicin (Garamycin, Gentacidin) |
|---|---|
| Description | Aminoglycoside antibiotic used for gram-negative bacterial coverage. Used commonly in combination with both an agent against gram-positive organisms and an agent that covers anaerobes. DOC (in conjunction with vancomycin) for infectious tenosynovitis and deep fascial space infections in patients who are allergic to penicillin. Dosing regimens are numerous and are adjusted based on CrCl and changes in volume of distribution. |
| Adult Dose | 1 mg/kg IV/IM q8h or 5-7 mg/kg IV/IM q24h |
| Pediatric Dose | 2.5 mg/kg IV/IM q8h |
| Contraindications | Documented hypersensitivity; non–dialysis-dependent renal insufficiency |
| Interactions | Coadministration with other aminoglycosides, cephalosporins, penicillins, and amphotericin B may increase nephrotoxicity; aminoglycosides enhance effects of neuromuscular blocking agents, thus prolonged respiratory depression may occur; coadministration with loop diuretics may increase auditory toxicity of aminoglycosides; possible irreversible hearing loss of varying degrees may occur (monitor regularly) |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Narrow therapeutic index (not intended for long-term therapy); caution in renal failure (not on dialysis), myasthenia gravis, hypocalcemia, and conditions that depress neuromuscular transmission; adjust dose in renal impairment |
These agents are used to induce and boost active immunity.
| Drug Name | Tetanus toxoid |
|---|---|
| Description | Used to induce active immunity against tetanus in selected patients. Immunizing agents of choice for most adults and children >7 y are tetanus and diphtheria toxoids. Necessary to administer booster doses to maintain tetanus immunity throughout life. Pregnant patients should receive only tetanus toxoid, not a diphtheria antigen-containing product. In children and adults, may administer into deltoid or midlateral thigh muscles. In infants, preferred site of administration is mid thigh laterally. |
| Adult Dose | Primary immunization: 0.5 mL IM; administer 2 injections 4-8 wk apart; third dose 6-12 mo after second injection Booster dose: 0.5 mL q10y |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; a history of any type of neurologic symptoms or signs following administration of this product; Food and Drug Administration (FDA) recommends that elective tetanus immunization be deferred during any outbreak of poliomyelitis because tetanus toxoid injections are an important cause of provocative poliomyelitis |
| Interactions | Patients receiving immunosuppressants, including corticosteroids or radiation therapy, may remain susceptible despite immunization because of poor immune response; cimetidine may enhance or augment delayed-hypersensitivity responses to skin-test antigens; avoid concurrent use of medication with systemic chloramphenicol because it may impair amnestic response to tetanus toxoid; concurrent use of tetanus immune globulin may delay development of active immunity by several days (interaction is nevertheless clinically insignificant and does not preclude concurrent use) |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Do not use to treat actual tetanus infections or for immediate prophylaxis of unimmunized individuals (use tetanus antitoxin instead, preferably human tetanus immune globulin); diminished antibody response to active immunization may be observed in patients receiving immunosuppressive therapy; better to defer primary diphtheria immunization until immunosuppressive therapy discontinued; routine immunization of symptomatic and asymptomatic HIV-infected persons is recommended |
These agents are used in the treatment of chronic paronychia. They have anti-inflammatory properties and cause profound and varied metabolic effects. Corticosteroids modify the body's immune response to diverse stimuli.
| Drug Name | Hydrocortisone (CortaGel, Cortaid, Dermacort, Westcort) |
|---|---|
| Description | An adrenocorticosteroid derivative suitable for application to skin or external mucous membranes. Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability. |
| Adult Dose | Apply sparingly to affected areas bid/qid |
| Pediatric Dose | Apply as in adults |
| Contraindications | Documented hypersensitivity; viral, fungal, and bacterial skin infections |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Prolonged use, applying over large surface areas, applying potent steroids, and using occlusive dressings may increase systemic absorption of corticosteroids and may cause Cushing syndrome, reversible HPA-axis suppression, hyperglycemia, and glycosuria |
These agents are used in the treatment of chronic paronychia.
| Drug Name | Clotrimazole (Lotrimin, Mycelex) |
|---|---|
| Description | Broad-spectrum antifungal agent that inhibits yeast growth by altering cell membrane permeability, causing death of fungal cells. Reevaluate diagnosis if no clinical improvement after 4 wk. |
| Adult Dose | Gently massage into affected area and surrounding skin areas bid for 2-6 wk |
| Pediatric Dose | Children: Not established Adolescents: Apply as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Not appropriate for treatment of systemic fungal infections; avoid contact with the eyes; if irritation or sensitivity develops, discontinue use and institute appropriate therapy |
The authors and editors of eMedicine gratefully acknowledge the contributions of previous authors, Amy K Rontal, MD, and Heatherlee Bailey, MD, to the development and writing of this article.
| Media file 1: A paronychia can progress to a felon if left untreated. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 2: A herpetic whitlow. Image courtesy of Glen Vaughn, MD. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 3: Paronychia incision and drainage. | |
![]() | View Full Size Image | Media type: Image |
Article Last Updated: Feb 11, 2008